Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
|The following article is part of conference coverage from the 2018 Genitourinary Cancers Symposium in San Francisco. Renal and Urology News' staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from GU 2018.|
SAN FRANCISCO—Survival varies among different types of non-urothelial bladder cancers, according to study findings presented at the 2018 Genitourinary Cancers Symposium.
Patients with adenocarcinoma of the bladder had the greatest median survival (179 months), with a 5-year disease-specific survival (DSS) rate of 58%, followed by patients with sarcomas (median survival 23 months, with a 5-year DSS rate of 47%), and squamous cell carcinomas (median survival time of 15 months, with a 5-year DSS rate of 37%). The worse survival was for patients with small cell carcinomas (median survival time of 17 months, with a 5-year DSS rate of 31%.
Using Surveillance, Epidemiology, and End Results (SEER) program database, Jeanny B. Aragon-Ching, MD, of the Inova Schar Cancer Institute in Fairfax, Virginia, and Donald Henson, MD, of the Uniformed Services University of Health Sciences in Bethesda, Maryland, identified 235,537 incident cases of bladder cases during the period 1988 to 2008. The non-urothelial bladder cancers included 3096 squamous cell carcinomas, 859 small cell carcinomas, 89 sarcomas, and 671 adenocarcinomas.
“Non-urothelial cancers have a uniformly less favorable survival compared to urothelial cancers, highlighting the need for improved therapeutic strategies in these cohorts of patients,” the authors concluded in a study poster.
Aragon-Ching JB, Henson D. Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988–2008. Presented at the 2018 Genitourinary Cancers Symposium, held in San Francisco from Feb. 8-10. Abstract 425.